U.S. MarketsIMPORTANT

Bristol-Myers Squibb Company (BMY) Q3 2026 (USD): Adj. EPS 1.35 (exp. 1.10), Revenue 13.07bln (exp. 12.72bln)

ORIGINAL · NewsquawkBristol-Myers Squibb Company (BMY) Q3 2026 (USD): Adj. EPS 1.35 (exp. 1.10), Revenue 13.07bln (exp. 12.72bln)Read originalHide original

Other Metrics: Growth Portfolio revenue 7.66bln, +12% Y/Y. Legacy Portfolio revenue 5.42bln, +1% Y/Y. Eliquis revenue 4.69bln, +25% Y/Y. US revenue 9.07bln, +9% Y/Y. International revenue 4.0bln, +3% Y/Y. FY outlook Adj. EPS 6.35-6.55 (exp. 6.34), Revenue 49.75-50.25bln (exp. 49.9bln). Commentary: Growth Portfolio performance was driven by Opdivo Qvantig, Breyanzi, Reblozyl, Camzyos and Opdualag, while Eliquis growth offset continued generic competition in the Legacy Portfolio.

StockNow breaking-news AI analysis

Bristol Myers Squibb reported Q3 growth across stated portfolios and geographies, while Reuters described lower EPS and higher revenue guidance versus prior ranges and cited a quarterly charge.

News detail

Other Metrics: Growth Portfolio revenue 7.66bln, +12% Y/Y. Legacy Portfolio revenue 5.42bln, +1% Y/Y. Eliquis revenue 4.69bln, +25% Y/Y. US revenue 9.07bln, +9% Y/Y. International revenue 4.0bln, +3% Y/Y. FY outlook Adj. EPS 6.35-6.55 (exp. 6.34), Revenue 49.75-50.25bln (exp. 49.9bln). Commentary: Growth Portfolio performance was driven by Opdivo Qvantig, Breyanzi, Reblozyl, Camzyos and Opdualag, while Eliquis growth offset continued generic competition in the Legacy Portfolio.

1 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more